|
DE60205891T2
(de)
|
2001-03-12 |
2006-06-22 |
Intercept Pharmaceuticals, Inc. |
Steroide als agonisten für fxr
|
|
ES2609395T5
(es)
|
2004-03-12 |
2021-08-06 |
Intercept Pharmaceuticals Inc |
Tratamiento de la fibrosis usando ligandos de Fxr
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
EP2040713B1
(en)
|
2006-06-27 |
2014-06-18 |
Intercept Pharmaceuticals Inc. |
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
|
|
CN101679476B
(zh)
|
2007-01-19 |
2014-05-07 |
英特塞普特医药品公司 |
23取代的胆汁酸作为tgr5调节剂及其使用方法
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
AU2009276507B2
(en)
*
|
2008-07-30 |
2015-11-19 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
|
CN102325784B
(zh)
|
2008-11-19 |
2014-11-19 |
英特塞普特医药品公司 |
G蛋白偶联受体5(tgr5)调节剂及其使用方法
|
|
CN102316889B
(zh)
|
2008-11-26 |
2014-11-26 |
萨蒂奥根制药公司 |
组合物及使用方法
|
|
JP2012509891A
(ja)
|
2008-11-26 |
2012-04-26 |
サティオゲン ファーマシューティカルズ，インク． |
肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤
|
|
US20110257139A1
(en)
|
2008-12-19 |
2011-10-20 |
Royal College Of Surgeons In Ireland |
Treatment of diarrhoea
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
EP2995317A1
(en)
|
2010-05-26 |
2016-03-16 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
ITRM20100329A1
(it)
*
|
2010-06-15 |
2011-12-16 |
Franco Baldelli |
Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
EP2525223A1
(en)
*
|
2011-05-19 |
2012-11-21 |
Universiteit Maastricht |
In vitro method for predicting in vivo genotoxicity of chemical compounds.
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US11154559B2
(en)
|
2011-09-29 |
2021-10-26 |
Ethicon Endo-Surgery, Inc. |
Methods and compositions of bile acids
|
|
JP6217938B2
(ja)
|
2011-10-28 |
2017-10-25 |
ルメナ ファーマシューティカルズ エルエルシー |
小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
|
|
MX363161B
(es)
|
2011-10-28 |
2019-03-13 |
Lumena Pharmaceuticals Inc |
Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
CN104781272A
(zh)
|
2012-06-19 |
2015-07-15 |
英特塞普特医药品公司 |
奥贝胆酸的制备、用途和固体形式
|
|
US9777038B2
(en)
*
|
2012-10-26 |
2017-10-03 |
Intercept Pharmaceuticals, Inc. |
Process for preparing bile acid derivatives
|
|
AU2013352288B2
(en)
*
|
2012-11-28 |
2017-11-23 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
|
EA030152B1
(ru)
*
|
2013-05-14 |
2018-06-29 |
Интерсепт Фармасьютикалз, Инк |
11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
|
|
CN105636984A
(zh)
|
2013-06-13 |
2016-06-01 |
法斯特弗沃德制药有限公司 |
用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
|
|
CA2920017C
(en)
*
|
2013-08-01 |
2021-11-23 |
Frank J. Gonzalez |
Inhibitors of the farnesoid x receptor and uses in medicine
|
|
HRP20201953T1
(hr)
*
|
2013-09-11 |
2021-04-30 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
|
|
MX356006B
(es)
*
|
2013-10-18 |
2018-04-24 |
Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C |
Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
|
|
EP3985118A1
(en)
|
2013-11-22 |
2022-04-20 |
MiNA Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
|
CN106661548B
(zh)
|
2014-05-28 |
2020-12-11 |
儿童医院医疗中心 |
用于经由定向分化将前体细胞转化为胃组织的方法和系统
|
|
ES2938874T3
(es)
|
2014-05-29 |
2023-04-17 |
Bar Pharmaceuticals S R L |
Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1
|
|
US10238636B2
(en)
|
2014-09-24 |
2019-03-26 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
|
WO2016045480A1
(zh)
*
|
2014-09-28 |
2016-03-31 |
上海源力生物技术有限公司 |
一种奥贝胆酸的制备方法
|
|
WO2016061464A1
(en)
|
2014-10-17 |
2016-04-21 |
Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center |
In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
|
|
CA2966885A1
(en)
*
|
2014-11-06 |
2016-05-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
|
|
JP6724004B2
(ja)
|
2014-11-19 |
2020-07-15 |
エヌゼットピー ユーケー リミテッド |
ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
|
|
US20170327531A1
(en)
|
2014-11-19 |
2017-11-16 |
NZP UK Limited |
6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
|
|
CN107108688B
(zh)
|
2014-11-19 |
2019-10-29 |
Nzp英国有限公司 |
作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
|
|
CN107207559B
(zh)
|
2014-11-19 |
2019-10-25 |
Nzp英国有限公司 |
作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
US10519191B2
(en)
|
2014-11-26 |
2019-12-31 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
|
WO2016086115A1
(en)
*
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
|
TN2017000344A1
(en)
*
|
2015-02-06 |
2019-01-16 |
Intercept Pharmaceuticals Inc |
Pharmaceutical compositions for combination therapy
|
|
KR20170133339A
(ko)
|
2015-02-11 |
2017-12-05 |
이난타 파마슈티칼스, 인코포레이티드 |
Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
|
|
PL3277286T3
(pl)
|
2015-03-31 |
2021-11-08 |
Enanta Pharmaceuticals, Inc. |
Pochodne kwasu żółciowego jako agonisty fxr/tgr5 i sposoby ich stosowania
|
|
MX2017012893A
(es)
|
2015-04-07 |
2018-01-15 |
Intercept Pharmaceuticals Inc |
Composiciones farmaceuticas para terapias combinadas.
|
|
WO2016173493A1
(en)
*
|
2015-04-28 |
2016-11-03 |
Shanghai De Novo Pharmatech Co. Ltd. |
Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
|
|
EP3124080A1
(en)
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
|
WO2017053428A1
(en)
|
2015-09-21 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
CN108350020A
(zh)
*
|
2015-09-24 |
2018-07-31 |
英特塞普特医药品公司 |
用于制备胆汁酸衍生物的方法和中间体
|
|
TW201718621A
(zh)
*
|
2015-10-07 |
2017-06-01 |
英特賽普醫藥品公司 |
法尼醇x受體調節劑
|
|
IL243707A0
(en)
|
2016-01-20 |
2016-05-01 |
Galmed Res And Dev Ltd |
Treatment to regulate the microbiota in the intestine
|
|
US20200262865A1
(en)
*
|
2016-02-15 |
2020-08-20 |
Alexander Khoruts |
Compositions and methods for treating clostridium associated diseases
|
|
US20170233431A1
(en)
*
|
2016-02-17 |
2017-08-17 |
City Of Hope |
Bile acid derivatives and methods for synthesis and use
|
|
US10323061B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
|
US11419878B2
(en)
|
2016-03-28 |
2022-08-23 |
Intercept Pharmaceuticals, Inc. |
Medicine obtained by combining FXR agonist and ARB
|
|
KR102377338B1
(ko)
*
|
2016-04-13 |
2022-03-21 |
인터셉트 파마슈티컬즈, 인크. |
암의 치료 방법
|
|
WO2017192997A1
(en)
|
2016-05-05 |
2017-11-09 |
Children's Hospital Medical Center |
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
KR102269305B1
(ko)
|
2016-06-13 |
2021-06-25 |
길리애드 사이언시즈, 인코포레이티드 |
Fxr (nr1h4) 조정 화합물
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
CN109963567A
(zh)
*
|
2016-09-30 |
2019-07-02 |
英特塞普特医药品公司 |
胆汁酸衍生物的结晶形式
|
|
NZ753051A
(en)
|
2016-11-04 |
2023-03-31 |
Children’S Hospital Medical Center |
Liver organoid compositions and methods of making and using same
|
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
|
ES2918698T3
(es)
|
2016-11-29 |
2022-07-19 |
Enanta Pharm Inc |
Proceso para la preparación de derivados del ácido biliar de las sulfonilureas
|
|
KR102807995B1
(ko)
|
2016-12-05 |
2025-05-16 |
칠드런즈 호스피탈 메디칼 센터 |
결장 유사장기 및 이를 제조 및 사용하는 방법
|
|
US10472386B2
(en)
|
2017-02-14 |
2019-11-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR agonists and methods of use thereof
|
|
US20180256600A1
(en)
*
|
2017-03-07 |
2018-09-13 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
TW201832768A
(zh)
*
|
2017-03-07 |
2018-09-16 |
英特賽普醫藥品公司 |
治療癌症的方法
|
|
PT3600309T
(pt)
|
2017-03-28 |
2022-10-03 |
Gilead Sciences Inc |
Combinações terapêuticas para o tratamento de doenças hepáticas
|
|
EP3600293A1
(en)
|
2017-03-30 |
2020-02-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
WO2018187804A1
(en)
|
2017-04-07 |
2018-10-11 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonyl carbamate bile acid derivatives
|
|
JP7248586B2
(ja)
|
2017-04-14 |
2023-03-29 |
チルドレンズ ホスピタル メディカル センター |
複数ドナー幹細胞組成物およびそれを作製する方法
|
|
CA3070837A1
(en)
|
2017-07-24 |
2019-01-31 |
Intercept Pharmaceuticals, Inc. |
Isotopically labeled bile acid derivatives
|
|
US11447773B2
(en)
|
2017-09-08 |
2022-09-20 |
Mina Therapeutics Limited |
Stabilized HNF4A saRNA compositions and methods of use
|
|
EP3694603A4
(en)
|
2017-10-10 |
2021-07-14 |
Children's Hospital Medical Center |
ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
|
|
US12379372B2
(en)
|
2017-12-21 |
2025-08-05 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
SG11202100533VA
(en)
|
2018-07-26 |
2021-02-25 |
Childrens Hospital Med Ct |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
|
US11208571B2
(en)
|
2018-08-08 |
2021-12-28 |
University Of Maryland, College Park |
Methods for nondestructive dispersing of carbon nanomaterials in water
|
|
SG11202102431YA
(en)
|
2018-09-12 |
2021-04-29 |
Childrens Hospital Med Ct |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
DK3911647T3
(da)
|
2019-01-15 |
2024-02-26 |
Gilead Sciences Inc |
Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
|
|
EP3920937A4
(en)
*
|
2019-02-04 |
2022-11-02 |
Intercept Pharmaceuticals, Inc. |
TREATMENT AND PREVENTION OF INFLAMATORY BOWEL DISEASES WITH A BILE ACID DERIVATIVE
|
|
CN118388474A
(zh)
|
2019-02-19 |
2024-07-26 |
吉利德科学公司 |
Fxr激动剂的固体形式
|
|
AU2020284135A1
(en)
|
2019-05-30 |
2022-01-06 |
Intercept Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease
|
|
CA3141807A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
CN112142814B
(zh)
*
|
2019-06-26 |
2021-09-28 |
江苏吉贝尔药业股份有限公司 |
牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
|
|
US20220241376A1
(en)
|
2019-07-18 |
2022-08-04 |
Enyo Pharma |
Method for decreasing adverse-effects of interferon
|
|
CA3159163A1
(en)
|
2020-01-15 |
2021-07-22 |
Raphael Darteil |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
US20240100125A1
(en)
|
2021-01-14 |
2024-03-28 |
Enyo Pharma |
Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
|
|
CA3213217A1
(en)
|
2021-04-28 |
2022-11-03 |
Raphael Darteil |
Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
|
|
CN119950519B
(zh)
*
|
2025-01-07 |
2025-11-21 |
山东省海洋科学研究院(青岛国家海洋科学研究中心) |
奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用
|